Different Biotechnology Companies have actively participated in extended report from the Diario Vasco daily newspaper. Among these Companies, VIVEbiotech´s CEO, put a reasoned viewpoint  considering that there are some Companies, as VIVEbiotech, that have been seeding during years allowing that Guipuzcoa is already a relevant area in the biotechnology sector.

VIVEbiotech has become a partner of Alliance for Regenerative Medicine 

Alliance for Regenerative Medicine (ARM) is the preeminent global advocate for regenerative and advanced therapies. ARM fosters research, development, investment and commercialization of transformational treatments and cures for patients worldwide.

This year, VIVEbiotech´s team will also participate in the 23^rd edition of Europe's largest partnering conference. 

Juan Carlos Ramirez, Chief Technology/Scientific Officer and Natalia Elizalde, Business Development Director, will be present at this event that will be hold in Berlin.

Please, do not hesitate to contact us to organize a meeting there so we will find a specific slot from the 6^th to the 8^th of November.

VIVEbiotech´s main interests are:

• Meeting with Companies developing its own Gene Therapy pipeline that are looking for a flexible Company able to adapt to its requirements in terms of Lentiviral vector development and manufacture.
• Meeting with Companies with interest in Lentisoma´s vector Technology (Non-integrative episomal lentiviral vector) to discuss about collaborative options.
• Building a strong network allowing us to continue positioning as key players in viral vector manufacture field.

VIVEbiotech will exhibit at the European Society Gene and Cell Therapy annual event that will be hold in Berlin from the 17^th to the 18^th of October.

ESGCT annual congress is considered as the more relevant event in Europe related to Advanced Therapies.

VIVEbiotech as an expert in Lentiviral vector manufacture will have the opportunity to meet with different Companies and Applied research institutions about its CDMO services and about Lentisoma technology.

Specifically, Juan Carlos Ramirez, Chief Technology/Scientific Officer and Natalia Elizalde, Business Development Director, will participate.

We will be very pleased to organize a meeting with you at this event.

As commented in the prior press release published at our webpage, here it is enclosed the poster `presented at European Haematology Association (EHA) Congress.

The poster entitled “Optimization of Transduction Conditions With GMP Like Lentiviral Vectors For The Gene Therapy Of Piruvate Kinase Deficiecy” was presented at European Hematology Association congress hold in Madrid from 22nd to the 25th of June.

The authors of these posters are:

• Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT)
• Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
• Unidad Mixta de Terapias Avanzadas. Instituto de Investigación Sanitaria Fundación Jiménez
• VIVEbiotech (responsible for the manufacturing of Lentiviral vectors)

As shown in the poster, this work has been financed with the support of the USA-based leader Company in Gene Therapy, Rocket Pharma.

The 26th of May, Juan Carlos Ramirez (Scientific Director), gave an oral presentation in the Conference organized by Fundación Victor Grifols I Lucas entitled “CRISPR… Does Genetic revolution have limit?”.